An open-label trial of JAK 1/2 blockade in progressive IFIH1 -associated neuroinflammation by Kothur, Kavitha et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An open-label trial of JAK 1/2 blockade in progressive
IFIH1               -associated neuroinflammation
Citation for published version:
Kothur, K, Bandodkar, S, Chu, S, Wienholt, L, Johnson, A, Barclay, P, Brogan, PA, Rice, GI, Crow, YJ &
Dale, RC 2018, 'An open-label trial of JAK 1/2 blockade in progressive               IFIH1               -associated
neuroinflammation' Neurology, vol. 90, no. 6, pp. 289-291. DOI: 10.1212/WNL.0000000000004921
Digital Object Identifier (DOI):
10.1212/WNL.0000000000004921
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Neurology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
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IFIH1 gain-of-function causes a spectrum of neuroinﬂammatory phenotypes associated with
enhanced type I interferon production and Janus kinase (JAK)/signal transducer and activator
of transcription (STAT) pathway activation.1,2 Patients most often present in infancy, variably
exhibiting spasticity, dystonia, seizures, and acquired microcephaly. We report the use of
ruxolitinib, a JAK 1/2 blocker, in the treatment of early-onset, progressive neurologic disease
due to an IFIH1 mutation.
Case report
A 3-year-old boy born to unrelated white European parents developed normally until age 8
months, after which he experienced developmental regression with loss of trunk and head
control so that he could no longer sit or hold objects. The following 8 months were
characterized by sterile pyrexias, irritability, increasing spasticity, and exaggerated startle
responses to sounds (video, links.lww.com/WNL/A107). At age 16 months, he was mi-
crocephalic, small, and centrally hypotonic with peripheral spasticity (table e-1, links.lww.
com/WNL/A109). CSF was unremarkable except for elevated neopterin. Neuroimaging
revealed mildly delayed myelination and no calciﬁcation. Genetic testing identiﬁed a de
novo heterozygous p. Arg779Cys IFIH1 substitution, as previously reported in a patient
dying at age 3.5 years of a fulminant lupus-like syndrome on a background of neonatal-onset
severe developmental delay (F376 in Rice et al.1). There was a marked upregulation of
interferon-stimulated gene (ISG) transcripts in blood, a reliable biomarker of IFIH1-related
disease.3
Oral prednisolone was begun at age 16 months, 2 mg/kg for 2 months, followed by weaning
over 6 months, and IV immunoglobulin at age 20 months, 1 g/kg monthly for 3 months,
with temporary beneﬁts in head and trunk control and decreased irritability and pyrexias.
However, these gains were lost on weaning. Given progressive hypertonia and de-
velopmental stagnation, 16 months after disease onset he was begun on ruxolitinib 2.5 mg
twice daily, increased to 5 mg twice daily 6 weeks later.4 Over the next 19 months, he
regained independent sitting and began using a walker (video, links.lww.com/WNL/
A107). Hand function improved so that he could ﬁnger feed, pick up and throw objects, use
an iPad, and turn taps on and oﬀ. He could understand multistep sentences, although his
expressive language remained limited to 5–6 words. These clinical observations were
reﬂected in improved functional motor scores (table e-1, links.lww.com/WNL/A109;
ﬁgure e-1, links.lww.com/WNL/A108; and video). Erythrocyte sedimentation rate and
platelet count decreased on treatment, and repeat MRI at age 42 months demonstrated
progressive, albeit still mildly delayed, myelination, without atrophy or calciﬁcation (ﬁgures
e-2 and e-3).
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CSF samples, all acellular, were tested for 32 cytokines and
chemokines and compared with 20 noninﬂammatory pedi-
atric controls.5 CSF collected before ruxolitinib treatment, at
ages 10 and 24 months, demonstrated elevated levels of
neopterin, interferon-α, CXCL10, CXCL11, CXCL1, CCL2,
and CCL11. Serial measures at 3 time points after treatment
initiation (age 27, 30, and 33 months) revealed a fall in these
markers, albeit not to normal (ﬁgure). Ruxolitinib was mea-
sured during treatment, showing a trough concentration of
17.5 and 2.64 ng/mL in serum and CSF, respectively, with
a CSF penetrance of 15.1%. Treatment was well-tolerated,
with normal 3-monthly full blood counts, renal and liver
function, CSF and intraocular pressures, growth, consistently
negative JC and BK viral titers, and no side eﬀects.
Discussion
Our patient had an IFIH1 gain-of-function mutation resulting
in interferon-mediated inﬂammation signaling through the
type I interferon receptor and JAK1, as evidenced by an ele-
vation of ISGs in blood and proinﬂammatory cytokines and
chemokines in CSF. Ruxolitinib demonstrates a favorable
therapeutic eﬀect in patients with STING gain-of-function
mutations,4 suggesting that JAK inhibition might represent
a viable approach to blocking type I interferon signaling in the
broader monogenic interferonopathy grouping.6 The eﬃcacy
of JAK 1/2 blockade in type I interferon-driven neuro-
inﬂammation has not been addressed previously. Although
our report involves a single patient, and must be considered in
the context of a genotype associated with variability in clinical
outcome,1 we observed substantial developmental gains
against a background of previous regression and then de-
velopmental stagnation, combined with a positive eﬀect on
blood and CSF proinﬂammatory biomarkers. Ruxolitinib was
present in CSF, suggesting access to the CNS. No adverse
eﬀects occurred at the doses used. However, immunosup-
pression is a potential risk, and rebound cytokine storm has
been described on withdrawal.4,7 Given that we describe
Figure Inflammatory biomarkers during treatment with ruxolitinib
(A) CSF neopterin, (B–G) CSF cytokine/chemokine during treatment with ruxolitinib. Retrospective testing of CSF collected at ages 10 months and 24 months
revealed elevated levels of neopterin and cytokines/chemokines (interferon (IFN)–α, CXCL10, CXCL11, CCL2, CXCL1, and CCL11). Serial CSF measures at 3
further time points (27, 30, and 33months of age) over a 10-month period after initiation of ruxolitinib demonstrated an overall fall in all of these CSFmarkers.
(H) Similarly, serial blood interferon-stimulated gene (ISG) transcript scoreswere higher before ruxolitinib (at ages 20, 21, and 24months) than post ruxolitinib
(at ages 25, 26, and 27 months). The 95th centile of 20 noninflammatory controls is presented as a dotted line in each panel (P95C).
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a single case (Class IV evidence), this approach requires
evaluation in a larger number of patients with sequential de-
velopmental and neurologic assessment. JAK inhibition rep-
resents a promising approach to the treatment of type I
interferon-mediated autoinﬂammation, possibly including
CNS inﬂammation.
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